Skip to main content

Table 2 Baseline characteristics by study site

From: The heterogeneity of symptom reporting across study sites: a secondary analysis of a randomised placebo-controlled multicentre antimalarial trial

Country

Site

Patients

Age (years)

Patients under 5 years

Male sex

Weight (kg)

Baseline parasitaemiaa (/μl)

Baseline presence of fever

n

Median (IQR)

N (%)

N (%)

Median (IQR)

Median (IQR)

N (%)

Afghanistan

Jalalabad

311

14 (9.0—22.0)

23 (7.4%)

234 (75%)

41.0 (22.5—61.3)

1064.8 (666.7–2296.3)

89 (28.6%)

Laghman

120

11 (7.5—16.0)

6 (5.0)

71 (59%)

31.9 (21.8—46.9)

2194.4 (611.1–5750.0)

20 (16.7%)

Ethiopia

Arba Minch

371

16 (10.0—20.0)

43 (11.6%)

195 (53%)

47.0 (24.0—58.0)

12,500.0 (3037.0–52500.0)

1 (0.3%)

Metehara

209

16 11.0—27.0)

11 (5.3%)

136 (65%)

47.1 (29.0—55.5)

883.2 (314.4–21,250.0)

45 (21.5%)

Indonesia

Hanura

575

14 (8.0—27.0)

51 (8.9%)

300 (52%)

38.0 (21.3—52.0)

1674.1 (440.7–4633.3)

14 (2.4%)

Tanjung Leidong

425

17 (11.0—30.0)

19 (4.5%)

251 (59%)

49.0 (27.4—58.1)

7133.3 (4466.7–11,364.8)

100 (23.5%)

Vietnam

Dak O & Bu Gia Map

219

22 (16.0—32.0)

1 (0.5%)

184 (84%)

52.0 (45.0—60.0)

10,000.0 (4565.9–17,500.0)

13 (5.9%)

Krong Pa

106

25 (22.0—30.0)

0 (0%)

96 (91%)

55.0 (52.0—60.0)

10,000.0 (2351.9–25,000.0)

3 (2.8%)

Total

 

2,336

16 (10.0—26.0)

154 (6.6%)

1467 (63%)

46.6 (26.0—57.0)

3985.2 (963.0–12037.0)

285 (12.2%)

  1. aBaseline parasitaemia data were missing for 48 patients